ORDER NOW

Vascepa® (icosapent ethyl)

For adults on maximally tolerated statins with TG ≥150 mg/dL and established CVD or diabetes and ≥2 CVD risk factors

For patients with prior CV events, such as a heart attack or stroke, VASCEPA® (icosapent ethyl) is proven to reduce the risk of a life-threatening CV event[1-4]*

Retail fact sheet for VASCEPA

SUPPLIED AND MARKETED BY
Amarin Pharmaceuticals Ireland Limited

PRODUCT NAME
VASCEPA

GENERIC NAME
icosapent ethyl

PRODUCT WEBSITE
www.vascepahcp.com

PRODUCT INFORMATION (NDC)
1-gram capsules: 52937-001-20
0.5-gram capsules: 52937-003-40

DESCRIPTION
1-gram or 0.5-gram, amber-colored, liquid-filled, soft-gelatin capsules imprinted with VASCEPA

QUANTITY
Bottles of 120 1-gram capsules or 240 0.5-gram capsules

PRICE
For 120 1-gram capsules: $354.55
For 240 0.5-gram capsules: $414.81

WHOLESALER ORDERING INFORMATION
Please contact your wholesaler of choice to order VASCEPA.

CODES FOR WHOLESALER
ABC – AM21200
McKesson – AM24000
Cardinal – AM34000

PRODUCT EXPIRATION
See label for specific expiration dates.

PRESCRIPTION LEGEND
Prescription only.

STORAGE AND HANDLING REQUIREMENTS
Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). [See USP Controlled Room Temperature.] Keep out of reach of children.

PRODUCT RETURNS
Please contact your wholesaler for any returns.

Eligible patients can pay as little as $9 for a 90-day† supply with the VASCEPA Savings Card.

You can download the universal VASCEPA Savings Card at vascepahcp.com/savings‡

CV=cardiovascular; CVD=cardiovascular disease; NDC=National Drug Code; TG=triglyceride.
*Cardiovascular events including myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization.
†For eligible patients only. Maximum savings and other terms and conditions apply. See https://vascepa.copaysavingsprogram.com for details.
‡Universal Pharmacy Card (UPC) may be applied for any eligible patient by entering all 4 codes.

INDICATIONS AND LIMITATIONS OF USE

- VASCEPA® (icosapent ethyl) is indicated as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥150 mg/dL) and established cardiovascular disease or diabetes mellitus and 2 or more additional risk factors for cardiovascular disease
- VASCEPA is indicated as an adjunct to diet to reduce TG levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia

The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.

IMPORTANT SAFETY INFORMATION

- VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of its components

Please see additional Important Safety Information for VASCEPA on the back and accompanying full Prescribing Information for VASCEPA or go to www.vascepahcp.com.

Retail fact sheet for VASCEPA®

- Proven CV risk reduction in adult patients on maximally tolerated statins with elevated triglyceride levels (≥150 mg/dL) and established cardiovascular disease or diabetes mellitus and 2 or more additional risk factors for cardiovascular disease[1]
- VASCEPA has a well-established safety profile[1]
- The daily dose of VASCEPA is 4 g per day taken as two 1-g or four 0.5-g capsules BID with food[1]

Medical Information

For Medical Information, call 1-855-VASCEPA (827-2372) or email AmarinConnect@Amarincorp.com.

IMPORTANT SAFETY INFORMATION (cont'd)

- VASCEPA was associated with an increased risk (3% vs 2%) of atrial fibrillation or atrial flutter requiring hospitalization in a double-blind, placebo-controlled trial. The incidence of atrial fibrillation was greater in patients with a previous history of atrial fibrillation or atrial flutter
- It is not known whether patients with allergies to fish and/or shellfish are at an increased risk of an allergic reaction to VASCEPA. Patients with such allergies should discontinue VASCEPA if any reactions occur
- VASCEPA was associated with an increased risk (12% vs 10%) of bleeding in a double-blind, placebo-controlled trial. The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel or warfarin
- Common adverse reactions in the cardiovascular outcomes trial (incidence ≥3% and ≥1% more frequent than placebo): musculoskeletal pain (4% vs 3%), peripheral edema (7% vs 5%), constipation (5% vs 4%), gout (4% vs 3%) and atrial fibrillation (5% vs 4%)
- Common adverse reactions in the hypertriglyceridemia trials (incidence ≥1% more frequent than placebo): arthralgia (2% vs 1%) and oropharyngeal pain (1% vs 0.3%)
- Adverse Events, Product Complaints, or Special Situations may be reported by contacting AmarinConnect at 1-855-VASCEPA, emailing AmarinConnect@Amarincorp.com, or calling the FDA at 1-800-FDA-1088
- Patients receiving VASCEPA and concomitant anticoagulants and/or anti-platelet agents should be monitored for bleeding

Please see accompanying full Prescribing Information for VASCEPA or go to www.vascepahcp.com.

BID=twice daily.

References: 1. VASCEPA [package insert]. Bridgewater, NJ: Amarin Pharma, Inc.; 2021. **2.** Bhatt DL, Steg PG, Miller M, et al; for the REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. *N Engl J Med*. 2019;380(1):11-22. **3.** Bhatt DL, Steg PG, Miller M, et al. Reduction of cardiovascular events with icosapent ethyl–intervention trial. Presented at: American Heart Association Scientific Sessions; November 10-12, 2018; Chicago, IL. **4.** Bhatt DL, Steg PG, Miller M, et al; on behalf of the REDUCE-IT Investigators. Effects of icosapent ethyl on total ischemic events: from REDUCE-IT. *J Am Coll Cardiol*. 2019;73(22):2791-2802.

AMARIN®

Vascepa® (icosapent ethyl)

THE NEXT LEVEL OF HEART PROTECTION